Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

Under RFK Jr., HHS has canceled key vaccine meetings. Here's what that means for seasonal flu, bird flu, and childhood ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from ...

U.S. involvement in WHO flu meetings, the UK's approval of Moderna's RSV vaccine, efforts against a measles outbreak in Texas ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

This content summarizes current global health news, highlighting vaccine developments, disease outbreaks, and health ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.